title: Caspofungin versus liposomal amphotericin B: are they really comparable?
authors.forename: Leo
authors.initials: L
authors.lastname: Sekine
authors.forename: João
authors.initials: J
authors.lastname: Humbwavali
authors.forename: Fernando Herz
authors.initials: FH
authors.lastname: Wolff
authors.forename: Nêmora Tregnago
authors.initials: NT
authors.lastname: Barcellos
mesh_terms: D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D000077336:Caspofungin; D054714:Echinocandins / Q000009:adverse effects / Q000627:therapeutic use*; D005335:Fever of Unknown Origin / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host; D055666:Lipopeptides; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077336:Caspofungin